Brigham Hyde, CEO of Precision Health AI, explains the company is building out a data platform for oncology treatment. The firm is building products to serve pharma, life science companies, providers, and payers. In this podcast, Hyde explains how Precision Health AI can help oncologists determine stage of cancer and identify adverse effects.
Brigham Hyde, PhD
Precision Health AI
Dr. Brigham Hyde, PhD is the Founder and CEO of Precision Health AI. Hyde is a Research Affiliate at MIT and an Adjunct Professor and Lecturer at Tufts University Sackler School of Biomedical Science in the Department of Pharmacology. He has experience in preclinical drug development from CRO Wolfe Laboratories Inc. and has conducted research and published several articles in pharmacology and mitochondrial biology. He received his B.S. in Chemistry and a minor in Business Management from Northeastern University, as well as a Ph.D. in Pharmacology and Experimental Therapeutics from Tufts University Sackler School of Biomedical Science.
Meet Our Host
Healthegy Contributing Host Stephen Krupa is CEO of Healthedge, a software company focused on providing next-generation, business-transforming technology products to the healthcare payor market.